Original filing text · Part I

Item 3 — Quantitative and Qualitative Disclosures About Market Risk

Arrowhead Pharmaceuticals, Inc. · 10-Q · Q3 FY2026 · Period ended Jun 30, 2026

This is the extracted source text from the SEC filing. Formatting may differ from the original document.

There has been no material change in the Company’s exposure to market risk from that described in Item 7A of its Annual Report on Form 10-K for the fiscal year ended September 30, 2025.